130A Veritas In Silico Inc.Veritas In SilicoTSE Growth / Pharmaceuticals
0 posts
Veritas In Silico Inc. stock hit limit-up on Nov 19: what happened
It closed at ¥365 on Nov 19 (+¥80.0, +28.07%), limit-up, ranking #5 among the top gainers of all stocks on the Tokyo Stock Exchange.
No disclosures were found for this stock around that day. Share what you know in the posts below.
Changes are calculated from the closing prices this site collects daily; limit-up/down is an estimate based on the daily price limit. Please make your own investment decisions.
Veritas In Silico Inc. (130A) at a glance
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
Veritas In Silico Inc. (130A) Stock Price History
Veritas In Silico Inc. closed at ¥365 on Nov 19, 2026, +8.0% over 1 month, −27.7% over 1 year.
If you had invested ¥100,000 1 month ago, it would be worth ¥107,988 today (+8.0%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −8.4%, while this stock moved +8.0%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 19 (Thu) | ¥365 | +80 | +28.07% |
| Nov 18 (Wed) | ¥285 | +60 | +26.67% |
| Nov 17 (Tue) | ¥225 | −5 | −2.17% |
| Nov 16 (Mon) | ¥230 | −16 | −6.50% |
| Nov 13 (Fri) | ¥246 | −11 | −4.28% |
| Nov 12 (Thu) | ¥257 | +2 | +0.78% |
| Nov 11 (Wed) | ¥255 | −2 | −0.78% |
| Nov 10 (Tue) | ¥257 | +17 | +7.08% |
| Nov 9 (Mon) | ¥240 | −26 | −9.77% |
| Nov 6 (Fri) | ¥266 | −15 | −5.34% |
If you had invested ¥100,000 3 months ago, it would be worth ¥87,952 today (−12.0%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −9.0%, while this stock moved −12.0%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 19 (Thu) | ¥365 | +80 | +28.07% |
| Nov 18 (Wed) | ¥285 | +60 | +26.67% |
| Nov 17 (Tue) | ¥225 | −5 | −2.17% |
| Nov 16 (Mon) | ¥230 | −16 | −6.50% |
| Nov 13 (Fri) | ¥246 | −11 | −4.28% |
| Nov 12 (Thu) | ¥257 | +2 | +0.78% |
| Nov 11 (Wed) | ¥255 | −2 | −0.78% |
| Nov 10 (Tue) | ¥257 | +17 | +7.08% |
| Nov 9 (Mon) | ¥240 | −26 | −9.77% |
| Nov 6 (Fri) | ¥266 | −15 | −5.34% |
If you had invested ¥100,000 6 months ago, it would be worth ¥91,022 today (−9.0%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −1.8%, while this stock moved −9.0%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥365 | +21.3% |
| Oct 2026 | ¥301 | −31.3% |
| Sep 2026 | ¥438 | −1.8% |
| Aug 2026 | ¥446 | +9.9% |
| Jul 2026 | ¥406 | −5.8% |
| Jun 2026 | ¥431 | +3.6% |
| May 2026 | ¥416 | −8.2% |
If you had invested ¥100,000 1 year ago, it would be worth ¥72,277 today (−27.7%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +22.5%, while this stock moved −27.7%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥365 | +21.3% |
| Oct 2026 | ¥301 | −31.3% |
| Sep 2026 | ¥438 | −1.8% |
| Aug 2026 | ¥446 | +9.9% |
| Jul 2026 | ¥406 | −5.8% |
| Jun 2026 | ¥431 | +3.6% |
| May 2026 | ¥416 | −8.2% |
| Apr 2026 | ¥453 | −0.9% |
| Mar 2026 | ¥457 | −7.5% |
| Feb 2026 | ¥494 | +0.2% |
| Jan 2026 | ¥493 | +2.7% |
| Dec 2025 | ¥480 | −6.8% |
| Nov 2025 | ¥515 | ― |
If you had invested ¥100,000 3 years ago, it would be worth ¥12,146 today (−87.9%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +61.1%, while this stock moved −87.9%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥365 | −24.0% |
| 2025 | ¥480 | ― |
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Feb 2024). Please check the latest prices before trading.
Veritas In Silico Inc. (130A) financial indicators
PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.
Key features of Veritas In Silico Inc. (130A)
Business overview
The company is a drug discovery venture that uses AI-driven drug discovery to create medicines targeting messenger RNA (mRNA). It has upgraded its own drug discovery platform ibVIS, which combines informatics with experimental techniques, into aibVIS, which incorporates multiple AI systems and enables more efficient mRNA-targeted drug discovery. Small-molecule drug discovery targeting mRNA is a new approach that can address a range of diseases that were hard to target with conventional protein-targeting methods. Its business has two parts: a platform model, in which it conducts drug discovery research on mRNA-targeted small-molecule drugs jointly with several pharmaceutical companies, and a pipeline model, in which it holds its own pipeline, currently researching nucleic acid drugs mainly for rare diseases.
Summarized from the annual securities report (fiscal year ended December 2025) filed on EDINET.
Position within Pharmaceuticals (79 companies)
| PBR | 1.86x | Below the sector median of 1.87x (No. 38 from the lowest) |
|---|---|---|
| ROE | -55.14% | No. 46 in the sector (highest first); median 4.17% |
| Market cap | ¥2.4 bn | No. 75 in the sector (largest first) |
Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.
Price milestones
| 52-week high | ¥610 | 2025/12/24 |
|---|---|---|
| 52-week low | ¥225 | 11/17 |
| Current position | 36.4% | Where the low is 0% and the high is 100% (close on 11/19: ¥365) |
| Year to date | -24.0% | No. 49 of 77 in the sector (best first) |
| 1 year | -27.7% |
Based on closing prices (adjusted for stock splits, excluding dividends).
Kabutaro's ranking history
| Top 50 gainers | 3 times | Latest: 11/19 (No. 5) |
|---|---|---|
| Top 50 losers | 5 times | Latest: 11/9 (No. 10) |
Gainers and losers have been recorded since 9/2026.
Calculated as of 2026/11/19 17:30 JST. Updated every business day in the evening.
Recent disclosures (TDnet, in Japanese)
- 11/16 15:30筋萎縮性側索硬化症(ALS)の治療に向けた新たな核酸医薬品に関する特許権利化のお知らせ
- 11/11 15:302026年12月期 第3四半期決算短信〔日本基準〕(非連結)
- 11/11 15:302026 年12月期 通期業績予想の修正に関するお知らせ
- 11/11 15:30ドラッグデリバリーシステム「Perfusio(R)(パーフュージオ(R))」PMDA開発前相談の終了と今後の展望について
- 11/11 15:302026年12月期第3四半期 決算説明資料
- 11/02 17:00第5回(行使価額修正条項付)及び第6回から第9回新株予約権(ターゲット・イシュー・修正選択権付)の月間行使状況に関するお知らせ(2026年10月分)
- 11/02 15:30オーストラリア SyntaraとVeritas In Silico、mRNA標的化合物の共同探索研究に関する覚書締結のお知らせ
- 10/29 12:00第三者割当による第5回(行使価額修正条項付)及び第6回から第9回新株予約権(ターゲット・イシュー・修正選択権付)の払込完了のお知らせ
- 10/19 17:00東レ株式会社との共同創薬研究の進捗に伴うマイルストーン達成のお知らせ
- 10/13 17:00第三者割当による第5回(行使価額修正条項付)及び第6回から第9回新株予約権(ターゲット・イシュー)の発行ならびに、新株予約権買取契約締結のお知らせ
Show 1 more
- 10/13 17:00資金調達に関する補足説明資料
Filings from the past 12 months (11).
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No posts yet. Be the first to write something.
Write on the Veritas In Silico Inc. board
More Japanese stocks in English
- NEXT FUNDS TOPIX Core 30 Exchange Traded Fund1311
- NEXT FUNDS Nikkei 300 Index Exchange Traded Fund1319
- CCN Group Corporation131A
- iFreeETF Nikkei225 (Yearly Dividend Type)1320
- NEXT FUNDS Nikkei 225 Exchange Traded Fund1321
- Listed Index Fund China A Share (Panda) E Fund CSI3001322
- NEXT FUNDS Ibovespa Linked Exchange Traded Fund1325
- SPDR Gold Shares1326
- NEXT FUNDS Gold Price Exchange Traded Fund1328
- iShares Core Nikkei 225 ETF1329
- IN Holdings Co.,LTD.132A
- Listed Index Fund 2251330